Skip to content
Open Access
  • Home
  • Collections
    • High Impact Articles
    • Jawi Collection
    • Malay Medicine
    • Forensic
  • Search Options
    • UiTM Open Access
    • Search by UiTM Scopus
    • Advanced Search
    • Search by Category
  • Discovery Service
    • Sources
    • UiTM Journals
    • List UiTM Journal in IR
    • Statistic
  • About
    • Open Access
    • Creative Commons Licenses
    • COKI | Malaysia Open Access
    • User Guide
    • Contact Us
    • Search Tips
    • FAQs
Advanced
  • Search
  • Infusion reaction to inflixima...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Infusion reaction to infliximab biosimilar after transitioning from infliximab

Infusion reaction to infliximab biosimilar after transitioning from infliximab

Bibliographic Details
Main Authors: Reem Kashlan, MPH, Alexis B. Lyons, MD, Shanthi Narla, MD, Iltefat H. Hamzavi, MD
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:JAAD Case Reports
Subjects:
biosimilar
hidradenitis suppurativa
infliximab
infusion reaction
Online Access:http://www.sciencedirect.com/science/article/pii/S2352512620308584
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S2352512620308584

Similar Items

  • Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
    by: Bas JM Peters, et al.
    Published: (2021-02-01)
  • Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
    by: Fitzgerald T, et al.
    Published: (2021-01-01)
  • T-cell/histiocyte-rich large B-cell lymphoma in a 27-year-old with hidradenitis suppurativa, psoriasis, and vitiligo: Implications for screening
    by: Gautham Vellaichamy, MD, et al.
    Published: (2020-12-01)
  • The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses
    by: Rossella Talotta, et al.
    Published: (2017-10-01)
  • Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
    by: Evelien Moorkens, et al.
    Published: (2020-10-01)

© 2020 | Services hosted by the Perpustakaan Tun Abdul Razak, | Universiti Teknologi MARA | Disclaimer


Loading...